EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CRISPR-Cas System: The Current and Emerging Translational Landscape

Narendranath Bhokisham, Ethan Laudermilch, Lindsay L Traeger iD, Tonya D Bonilla, Mercedes Ruiz-Estevez, Jordan R Becker

Cells · 2023

DOI: 10.3390/cells12081103 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Narendranath Bhokisham und 5 weiteren Autor:innen. Beteiligte Einrichtung: Corporate Research Material Labs, 3M Center, 3M Company, Maplewood, MN 55144, USA. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 282 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR-Cas technology has rapidly changed life science research and human medicine. The ability to add, remove, or edit human DNA sequences has transformative potential for treating congenital and acquired human diseases. The timely maturation of the cell and gene therapy ecosystem and its seamless integration with CRISPR-Cas technologies has enabled the development of therapies that could potentially cure not only monogenic diseases such as sickle cell anemia and muscular dystrophy, but also complex heterogenous diseases such as cancer and diabetes. Here, we review the current landscape of clinical trials involving the use of various CRISPR-Cas systems as therapeutics for human diseases, discuss challenges, and explore new CRISPR-Cas-based tools such as base editing, prime editing, CRISPR-based transcriptional regulation, CRISPR-based epigenome editing, and RNA editing, each promising new functionality and broadening therapeutic potential. Finally, we discuss how the CRISPR-Cas system is being used to understand the biology of human diseases through the generation of large animal disease models used for preclinical testing of emerging therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsGene EditingAnimalsHumansEcosystemGenetic TherapyEpigenome

Stichwörter der Autor:innen

CRISPR animal modelsCRISPR-Casbase editorsclinical studygene editingprime editorstranslational research

Autor:innen und Institutionen

  • Corporate Research Material Labs, 3M Center, 3M Company, Maplewood, MN 55144, USA.

ORCID-Profile: Lindsay L Traeger

Zitieren

APA

Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruiz-Estevez, M., & Becker, J. R. (2023). CRISPR-Cas System: The Current and Emerging Translational Landscape. Cells. https://doi.org/10.3390/cells12081103

Vancouver

Bhokisham N, Laudermilch E, Traeger LL, Bonilla TD, Ruiz-Estevez M, Becker JR. CRISPR-Cas System: The Current and Emerging Translational Landscape. Cells. 2023. doi:10.3390/cells12081103

BibTeX
@article{Bhokisham2023,
  author = {Bhokisham, Narendranath and Laudermilch, Ethan and Traeger, Lindsay L and Bonilla, Tonya D and Ruiz-Estevez, Mercedes and Becker, Jordan R},
  title = {CRISPR-Cas System: The Current and Emerging Translational Landscape},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12081103}
}
Kostenlos starten →